83 FR 28448 - Notice Pursuant to the National Cooperative Research and Production Act of 1993- Medical Technology Enterprise Consortium

DEPARTMENT OF JUSTICE
Antitrust Division

Federal Register Volume 83, Issue 118 (June 19, 2018)

[Federal Register Volume 83, Number 118 (Tuesday, June 19, 2018)]
[Notices]
[Page 28448]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-13064]



[[Page 28448]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993-- Medical Technology Enterprise Consortium

    Notice is hereby given that, on May 3, 2018, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Medical Technology Enterprise 
Consortium (``MTEC'') has filed written notifications simultaneously 
with the Attorney General and the Federal Trade Commission disclosing 
changes in its membership. The notifications were filed for the purpose 
of extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Adventist Health System/Sunbelt, Inc. dba Florida 
Hospital, Orlando, FL; AegisCN LLC, Durham, NC; AmpliPhi Biosciences 
Corporation, San Diego, CA; Auckland UniServices Limited, Auckland, NEW 
ZEALAND; AxoGen Corporation, Alachua, FL; Axonova Medical, LLC, 
Philadelphia, PA; Blood Systems, Inc. dba Blood Systems Research 
Institute, Scottsdale, AZ; Blumio, Inc., San Francisco, CA; Board of 
Trustees of the Leland Stanford Junior University, Palo Alto, CA; 
Cellphire, Inc., Rockville, MD; Clinical Research Management, Inc. dba 
ICON Government and Public Health Solutions (ICON GPHS), Hinckley, OH; 
Cohen Veterans Bioscience, Inc., Cambridge, MA; Deloitte Consulting 
LLP, McLean, VA; Design Interactive, Inc., Orlando, FL; Disarm 
Therapeutics, Inc., Cambridge, MA; Dynport Vaccine Company LLC, 
Frederick, MD; Engineering and Computer Simulations, Inc., Orlando, FL; 
EyeSonix LLC, Long Beach, CA; Fibralign Corp., Union City, CA; FlexDex, 
Inc., Brighton, MI; FloTBI, Cleveland, OH; Fortuna Fix, London, UK; 
Imbed Biosciences, Fitchburg, WI; Kitware, Inc., Clifton Park, NY; 
LayerBio, Inc., Arlington, MA; LifeLens Technologies, LLC, Warrington, 
PA; Massachusetts Eye and Ear Infirmary, Boston, MA; MVK 
Pharmaceuticals, LLC, Indianapolis, IN; National Trauma Institute dba 
Coalition for National Trauma Research, San Antonio, TX; New York 
University School of Medicine, New York, NY; Noveome Biotherapeutics, 
Inc., Pittsburgh, PA; Pendar Technologies LLC, Cambridge, MA; Pluristem 
LTD, Haifa, ISRAEL; Quantum Applied Science and Research, Inc., San 
Diego, CA; RegenFix, LLC, Toledo, OH; Renerva, LLC, Pittsburgh, PA; 
ReNetX Bio, Inc., New Haven, CT; SAVIR GmbH, Berlin, GERMANY; Scion 
NeuroStim, LLC, Raleigh, NC; Selfit Medical Ltd., Ramat Ha'sharon, 
ISRAEL; SOL-DEL MEDICAL LTD., KFAR SABA, ISRAEL; Southern Research 
Institute, Birmingham, AL; SRI International, Menlo Park, CA; 
TerumoBCT, Inc., Lakewood, CO; The Children's Hospital Corporation dba 
Boston Children's Hospital, Boston, MA; The Informatics Applications 
Group, Inc., Reston, VA; The Methodist Hospital Research Institute dba 
Houston Methodist Research Institute, Houston, TX; University of 
California, San Diego, San Diego, CA; University of California, San 
Francisco, San Francisco, CA; University of Kentucky Research 
Foundation, Lexington, KY; URO-RESEARCH, LLC, Houston, TX; West 
Virginia University Research Corporation, Morgantown, WV; WESTAT, Inc., 
Rockville, MD; and Yale University, New Haven, CT, have been added as 
parties to this venture.
    Also, Aequor, Inc., Oceanside, CA; Brainpaths LLC, Las Vegas, NV; 
Combat Wounded Veteran Challenge, Inc., Saint Petersburg, FL; Infinite 
Arthroscopy, Inc., Cleveland Heights, OH; Institute for Applied 
Neurosciences, Charleston, SC; Kestrel Corporation, Albuquerque, NM; 
LifeLink Foundation, Inc., Tampa, FL; Maryland Development Center, 
Baltimore, MD; Nerves Incorporated, Dallas, TX; Neuroplast BV, 
Maastricht, THE NETHERLANDS; Northwestern University, Evanston, IL; 
NovaHep AB, Gothenburg, SWEDEN; Pertexa Healthcare Technologies, Inc., 
Ridgecrest, CA; The University of Cincinnati, Department of Surgery, 
Cincinnati, OH; Trideum BioSciences, Frederick, MD; University of South 
Carolina, Columbia, SC; University of Utah, Salt Lake City, UT; and 
Vapogenix, Inc., Houston, TX, have withdrawn as parties to this 
venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MTEC intends to file additional 
written notifications disclosing all changes in membership.
    On May 9, 2014, MTEC filed its original notification pursuant to 
Section 6(a) of the Act. The Department of Justice published a notice 
in the Federal Register pursuant to Section 6(b) of the Act on June 9, 
2014 (79 FR 32999).
    The last notification was filed with the Department on January 18, 
2018. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on March 12, 2018 (83 FR 10751).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2018-13064 Filed 6-18-18; 8:45 am]
 BILLING CODE 4410-11-P